<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.02">
 <iati-activity hierarchy="1" iati-activities:version="2.02" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <iati-identifier>XM-DAC-903-SII-39488</iati-identifier>
  <reporting-org ref="XM-DAC-903" type="40">
   <narrative xml:lang="EN">International Finance Corporation</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">Biological E</narrative>
  </title>
  <description type="2">
   <narrative xml:lang="EN">i.	Children and patients reached: The Project will increase the availability of affordable vaccines which can prevent potentially-fatal childhood diseases. By supplying vaccines to the Government of India, the Company will support India&apos;s UIP and contribute to reduction in infant and child mortality levels in the country.  
ii.	Direct and indirect employment creation:  Through this investment, will be able to expand its operations and create around additional high-quality jobs in India by 2022. The Project is also expected to create indirect employment relating to construction, manufacturing and distribution activities of the company. 
iii.	Research and Development: The Company invests significantly in Research and Development which is key to building a pipeline of products for under-met medical needs. The Company plans to launch several new products in India and other developing countries over the next five years.
iv.	Building domestic manufacturing capacity: By growing within India, BioE will contribute to promoting the development of the country&apos;s private sector and overall economic growth through its manufacturing facilities. The expansion of the domestic manufacturing capacity of the Company fits with the &quot;Make in India&quot; initiative launched by the government to make India a destination for production of goods and to boost the national economy.</narrative>
  </description>
  <description type="1">
   <narrative xml:lang="EN">table, .k-table{ border-collapse:collapse; width:100%; table-layout:fixed; margin-bottom: 15px;} .k-table, .k-table td, table, table td {outline: 0;border: 1px solid #000; } .k-table td, table td { padding: 5px; }        Biological E Limited (BioE or the Company), based in Hyderabad, India, develops and manufactures vaccines which are supplied within India and to other developing and middle-income countries either directly or through supplies to United Nations Childrens Fund (UNICEF) and the Global Alliance for Vaccines and Immunizations (GAVI). The Company is World Health Organization (WHO) pre-qualified for the liquid pentavalent vaccine (LPV) and the Japanese encephalitis (JE) vaccine. In pharmaceuticals, the Company manufactures generic formulations for the Indian market.        &#xA0;    The Company is now aiming to scale up its product offerings to include a wider range of vaccines and is setting up new manufacturing facilities in Shameerpet, Hyderabad, India for these products (the Project).        &#xA0;   Immunization prevents illnesses from vaccine-preventable diseases, thus aiding in prevention of disability and death, in addition to lowering costs of healthcare and preventing productivity losses due to these illnesses. Indias Universal Immunization Programme (UIP), introduced in 1985, has made great progress in expanding Routine Immunization (RI) coverage across the country, and today, it is one of the largest programmes of its kind in the world. The Project will support a research-driven mid-cap company to diversify its product range and increase access to good quality affordable vaccines in India and other developing countries, create direct and indirect jobs and increase manufacturing capacity in India.</narrative>
  </description>
  <participating-org role="4" type="70">
   <narrative xml:lang="EN">BIOLOGICAL E. LIMITED</narrative>
  </participating-org>
  <participating-org activity-id="XM-DAC-903-SII-39488" ref="XM-DAC-903" role="1" type="40"></participating-org>
  <activity-status code="2"></activity-status>
  <activity-date iso-date="2017-09-18" type="1"></activity-date>
  <activity-date iso-date="2018-10-22" type="2"></activity-date>
  <contact-info type="1">
   <organisation>
    <narrative xml:lang="EN">International Finance Corporation</narrative>
   </organisation>
   <telephone>+12024733800</telephone>
   <email>ccspg@ifc.org</email>
   <website>www.ifc.org</website>
   <mailing-address>
    <narrative xml:lang="EN">2121 Pennsylvania Avenue, NW Washington DC 20433</narrative>
   </mailing-address>
  </contact-info>
  <contact-info type="2">
   <mailing-address>
    <narrative xml:lang="EN">Contact Person: Anil Kumar Chiti   Company Name: Biological E Limited   Address: Plot no. 623-H, Road no. 35, Jubilee Hills, Hyderabad  500 033. INDIA   Email:    Anil.Chiti@biologicale.com         Phone: +91 40 3012 8309</narrative>
   </mailing-address>
  </contact-info>
  <contact-info type="2">
   <mailing-address>
    <narrative xml:lang="EN">table, .k-table{ border-collapse:collapse; width:100%; table-layout:fixed; margin-bottom: 15px;} .k-table, .k-table td, table, table td {outline: 0;border: 1px solid #000; } .k-table td, table td { padding: 5px; }    Contact Person: Anil Kumar Chiti  Company Name: Biological E Limited  Address: Plot no. 623-H, Road no. 35, Jubilee Hills, Hyderabad  500 033. INDIA  Email:    Anil.Chiti@biologicale.com        Phone: +91 40 3012 8309</narrative>
   </mailing-address>
  </contact-info>
  <recipient-country code="IN" percentage="100">
   <narrative xml:lang="EN">India</narrative>
  </recipient-country>
  <location ref="IN-India">
   <location-reach code="1"></location-reach>
   <location-id code="1453782" vocabulary="G1"></location-id>
   <name>
    <narrative xml:lang="EN">table, .k-table{ border-collapse:collapse; width:100%; table-layout:fixed; margin-bottom: 15px;} .k-table, .k-table td, table, table td {outline: 0;border: 1px solid #000; } .k-table td, table td { padding: 5px; }       The Company has five manufacturing facilities in India and Research and Development facilities in India and France. The Project will be carried out at the new and existing vaccines manufacturing facility in Shameerpet, Hyderabad, India.</narrative>
   </name>
   <description>
    <narrative xml:lang="EN">Location description</narrative>
   </description>
   <activity-description>
    <narrative xml:lang="EN">A description that qualifies the activity taking place at the location.</narrative>
   </activity-description>
   <administrative code="1453782" level="1" vocabulary="G1"></administrative>
   <point srsName="http://www.opengis.net/def/crs/EPSG/0/4326">
    <pos>22.0000000000 79.0000000000</pos>
   </point>
   <exactness code="2"></exactness>
   <location-class code="1"></location-class>
   <feature-designation code="ADMF"></feature-designation>
  </location>
  <sector code="325" percentage="100" vocabulary="11" vocabulary-uri="http://www.census.gov/cgi-bin/sssd/naics/naicsrch?chart=2012">
   <narrative xml:lang="EN">G-FA - Pharmaceuticals and Medicine Manufacturing</narrative>
  </sector>
  <country-budget-items vocabulary="1">
   <budget-item code="7.2.1" percentage="100" vocabulary="1">
    <description>
     <narrative xml:lang="EN">Total: $60.00 million</narrative>
    </description>
   </budget-item>
  </country-budget-items>
  <collaboration-type code="6"></collaboration-type>
  <default-flow-type code="35"></default-flow-type>
  <default-finance-type code="411"></default-finance-type>
  <default-aid-type code="C01" vocabulary="1"></default-aid-type>
  <default-tied-status code="5"></default-tied-status>
  <budget type="1">
   <period-start iso-date="2017-09-18"></period-start>
   <period-end iso-date="2018-06-30"></period-end>
   <value currency="USD" value-date="2017-09-18">60000000</value>
  </budget>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2017-09-18"></transaction-date>
   <value currency="USD" value-date="2017-09-18">60000000</value>
   <receiver-org>
    <narrative xml:lang="EN">BIOLOGICAL E. LIMITED</narrative>
   </receiver-org>
   <flow-type code="35"></flow-type>
   <finance-type code="411"></finance-type>
  </transaction>
  <document-link format="TEXT/HTML" url="https://disclosures.ifc.org/#/projectDetailSII/39488">
   <title>
    <narrative xml:lang="EN">Summary of Investment Information - Anticipated Impact Measurement &amp; Monitoring (AIMM) Assessment and Main Environmental &amp; Social Risks and Impacts of the Project</narrative>
   </title>
   <category code="A12"></category>
   <language code="EN"></language>
  </document-link>
  <document-link format="TEXT/HTML" url="https://disclosures.ifc.org/#/projectDetailSII/39488">
   <title>
    <narrative xml:lang="EN">Summary of Investment Information</narrative>
   </title>
   <category code="A12"></category>
   <language code="EN"></language>
  </document-link>
 </iati-activity>
</iati-activities>
